Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:CYPH NASDAQ:KLRS NASDAQ:SNSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.68+1.2%$2.18$1.07▼$6.18$101.34M1.161.02 million shs1.31 million shsCYPHCypherpunk Technologies$1.09-9.6%$0.84$0.23▼$3.70$105.98M-0.093.91 million shs2.46 million shsKLRSKalaris Therapeutics$4.90-6.1%$6.50$2.14▼$11.88$116.58M0.1597,646 shs33,843 shsSNSESensei Biotherapeutics$20.43+3.1%$28.89$5.25▼$36.76$27.40M-0.1830,397 shs40,624 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-2.89%-6.67%-68.18%-22.58%CYPHCypherpunk Technologies0.00%-8.82%+20.82%+52.84%+165.28%KLRSKalaris Therapeutics0.00%-3.54%-25.64%-43.35%+489,999,900.00%SNSESensei Biotherapeutics0.00%-12.69%-30.08%+124.75%+200.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$1.68+1.2%$2.18$1.07▼$6.18$101.34M1.161.02 million shs1.31 million shsCYPHCypherpunk Technologies$1.09-9.6%$0.84$0.23▼$3.70$105.98M-0.093.91 million shs2.46 million shsKLRSKalaris Therapeutics$4.90-6.1%$6.50$2.14▼$11.88$116.58M0.1597,646 shs33,843 shsSNSESensei Biotherapeutics$20.43+3.1%$28.89$5.25▼$36.76$27.40M-0.1830,397 shs40,624 shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-2.89%-6.67%-68.18%-22.58%CYPHCypherpunk Technologies0.00%-8.82%+20.82%+52.84%+165.28%KLRSKalaris Therapeutics0.00%-3.54%-25.64%-43.35%+489,999,900.00%SNSESensei Biotherapeutics0.00%-12.69%-30.08%+124.75%+200.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50227.38% UpsideCYPHCypherpunk Technologies 1.00SellN/AN/AKLRSKalaris Therapeutics 2.75Moderate Buy$15.60218.37% UpsideSNSESensei Biotherapeutics 2.00Hold$40.0095.79% UpsideCurrent Analyst Ratings BreakdownLatest SNSE, KLRS, CYPH, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/14/2026KLRSKalaris Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/13/2026KLRSKalaris Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/13/2026KLRSKalaris Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$26.00 ➝ $25.004/24/2026SNSESensei Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/22/2026CYPHCypherpunk Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)4/21/2026SNSESensei Biotherapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/20/2026SNSESensei Biotherapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$50.004/16/2026KLRSKalaris Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$14.003/18/2026ALDXAldeyra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $2.003/17/2026ALDXAldeyra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.70 per shareN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/A$1.83 per shareN/AKLRSKalaris TherapeuticsN/AN/AN/AN/A$2.88 per shareN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$14.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%N/ACYPHCypherpunk Technologies$4.82M$0.07N/AN/AN/AN/A-55.13%-45.87%5/18/2026 (Estimated)KLRSKalaris Therapeutics-$43.44M-$2.15N/AN/AN/AN/A-72.78%-43.49%N/ASNSESensei Biotherapeutics-$21.08M-$16.67N/AN/AN/AN/A-83.59%-69.97%8/4/2026 (Estimated)Latest SNSE, KLRS, CYPH, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026CYPHCypherpunk Technologies-$0.0406-$0.46-$0.4194-$0.46N/AN/A5/15/2026Q4 2025SNSESensei Biotherapeutics-$0.62-$131.45-$130.83-$131.45N/AN/A5/12/2026Q1 2026KLRSKalaris Therapeutics-$0.52-$0.46+$0.06-$0.46N/AN/A5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A3/30/2026Q4 2025SNSESensei Biotherapeutics-$4.81-$3.74+$1.07-$3.74($4.85) millionN/A3/17/2026Q4 2025KLRSKalaris Therapeutics-$0.56-$0.44+$0.12-$0.44N/AN/A2/27/2026Q4 2025ALDXAldeyra Therapeutics-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACYPHCypherpunk TechnologiesN/AN/AN/AN/AN/AKLRSKalaris TherapeuticsN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72CYPHCypherpunk TechnologiesN/A35.5635.56KLRSKalaris TherapeuticsN/A12.1912.23SNSESensei BiotherapeuticsN/A5.065.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CYPHCypherpunk Technologies30.46%KLRSKalaris Therapeutics66.05%SNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%CYPHCypherpunk Technologies3.50%KLRSKalaris Therapeutics68.10%SNSESensei Biotherapeutics23.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million54.53 millionOptionableCYPHCypherpunk Technologies4097.68 million94.26 millionOptionableKLRSKalaris Therapeutics11023.79 million7.59 millionN/ASNSESensei Biotherapeutics401.34 million1.03 millionNot OptionableSNSE, KLRS, CYPH, and ALDX HeadlinesRecent News About These CompaniesMillennium management reports $89k Sensei Biotherapeutics share sales1 hour ago | investing.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Purchases $164,021.22 in StockMay 16 at 7:58 AM | insidertrades.comSensei Biotherapeutics (NASDAQ:SNSE) Lowered to "Sell" Rating by Wall Street ZenMay 16 at 2:26 AM | americanbankingnews.comSensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15 at 7:30 AM | businesswire.comSensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street AnalystsMay 5, 2026 | finance.yahoo.comSensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerMay 5, 2026 | businesswire.comSensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00April 28, 2026 | msn.comSensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | businesswire.comSensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateMarch 30, 2026 | businesswire.comSensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 25, 2026 | businesswire.comMerger deal renews Faeth in Sensei; Piktor brightens, stock jumpsFebruary 18, 2026 | bioworld.comBSensei Biotherapeutics stock soars after Faeth Therapeutics acquisitionFebruary 18, 2026 | investing.comSensei Biotherapeutics stock soars 230% after Faeth dealFebruary 18, 2026 | msn.comSensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private PlacementFebruary 18, 2026 | finance.yahoo.comSNSE stock surges to 21-month high – everything to know about its Faeth Therapeutics acquisitionFebruary 18, 2026 | msn.comSensei Biotherapeutics Expands Board, Adds Finance ExpertiseFebruary 13, 2026 | tipranks.comSensei Biotherapeutics Inc.February 1, 2026 | wsj.comEgle Therapeutics Appoints John Celebi as Chief Executive OfficerJanuary 7, 2026 | globenewswire.comSensei Biotherapeutics updates executive retention and compensation agreementsDecember 23, 2025 | msn.comSensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder James Peyer Sells 3,105 SharesDecember 11, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNSE, KLRS, CYPH, and ALDX Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$1.68 +0.02 (+1.20%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$1.68 0.00 (0.00%) As of 05/15/2026 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Cypherpunk Technologies NASDAQ:CYPH$1.08 -0.12 (-9.58%) As of 05/15/2026 04:00 PM EasternLeap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Kalaris Therapeutics NASDAQ:KLRS$4.90 -0.32 (-6.13%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$4.91 +0.01 (+0.20%) As of 05/15/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.Sensei Biotherapeutics NASDAQ:SNSE$20.43 +0.61 (+3.08%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$21.55 +1.12 (+5.48%) As of 05/15/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
